03:35 AM EDT, 08/13/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) said late Monday the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to its KYV-101 experimental therapy, which is being developed to treat progressive myasthenia gravis.

Myasthenia gravis is an autoimmune disorder associated with muscle weakness.

The designation allows Kyverna "to leverage on more expedited meetings and more senior FDA leadership involvement throughout the development cycle for KYV-101," the company said.

Price: 6.72, Change: +0.19, Percent Change: +2.91